Derivative exercise or conversion — not an open-market buy.
Traded Dec 17, 2025 · Filed Dec 19, 2025
Roivant Sciences's Reporting person sold $4.39M of Roivant Sciences shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$4,391,595
Shares × reported transaction price
37 days after results of Nov 10, 2025, 51 days before results of Feb 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −4.3% | +0.4% | −4.8% |
| 30 days | +1.3% | +0.1% | +1.2% |
| 90 days | +23.1% | −4.3% | +27.4% |
| 180 days | +37.8% | +8.7% | +29.1% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$4.38M of Roivant Sciences
Automatic saleDerivative exercise or conversion — not an open-market buy.